Structural analysis of the boronic acid β-lactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3
Authors:
- Robert A. BonomoRBRobert A. Bonomo
- Focco van Den AkkerFAFocco van Den Akker
Open Access
- 15 October 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258359
Abstract
Antimicrobial resistance (AMR) mediated by β-lactamases is the major and leading cause of resistance to penicillins and cephalosporins among Gram-negative bacteria. β-Lactamases, periplasmic enzymes that are widely distributed in the bacterial world, protect penicillin-binding proteins (PBPs), the major cell wall synthesizing enzymes, from inactivation by β-lactam antibiotics. Developing novel PBP inhibitors with a non-β-lactam scaffold could potentially evade this resistance mechanism. Based on the structural similarities between the evolutionary related serine β-lactamases and PBPs, we investigated whether the potent β-lactamase inhibitor, vaborbactam, could also form an acyl-enzyme complex with Pseudomonas aeruginosa PBP3. We found that this cyclic boronate, vaborbactam, inhibited PBP3 (IC50 of 262 μM), and its binding to PBP3 increased the protein thermal stability by about 2°C. Crystallographic analysis of the PBP3:vaborbactam complex reveals that vaborbactam forms a covalent bond with the catalytic S294. The amide moiety of vaborbactam hydrogen bonds with N351 and the backbone oxygen of T487. The carboxyl group of vaborbactam hydrogen bonds with T487, S485, and S349. The thiophene ring and cyclic boronate ring of vaborbactam form hydrophobic interactions, including with V333 and Y503. The active site of the vaborbactam-bound PBP3 harbors the often observed ligand-induced formation of the aromatic wall and hydrophobic bridge, yet the residues involved in this wall and bridge display much higher temperature factors compared to PBP3 structures bound to high-affinity β-lactams. These insights could form the basis for developing more potent novel cyclic boronate-based PBP inhibitors to inhibit these targets and overcome β-lactamases-mediated resistance mechanisms.Keywords
Funding Information
- National Institutes of Health, National Institute of Allergy and Infectious Diseases (R01AI100560, R01AI063517, R01AI072219)
- Cleveland Department of Veterans Affairs (1I01BX001974)
This publication has 49 references indexed in Scilit:
- Development of New Drugs for an Old Target — The Penicillin Binding ProteinsMolecules, 2012
- Unexpected Tricovalent Binding Mode of Boronic Acids within the Active Site of a Penicillin-Binding ProteinJournal of the American Chemical Society, 2011
- REFMAC5 for the refinement of macromolecular crystal structuresActa Crystallographica Section D Structural Biology, 2011
- Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains ofPseudomonas aeruginosaProceedings of the National Academy of Sciences, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenemInternational Journal of Antimicrobial Agents, 2008
- Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli , Pseudomonas aeruginosa , Staphylococcus aureus , and Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004